Case Studies Overview
-
Case #1: A 56-year-old man experienced significant improvement in Long COVID symptoms, including fatigue, brain fog, and exercise intolerance, after a 15-day course of nirmatrelvir/ritonavir. Symptoms recurred to some extent but at an improved baseline.
-
Case #2: A 45-year-old woman reported improved energy, physical strength, and mental clarity after a 15-day course, with complete resolution of orthostatic intolerance symptoms.
-
Case #3: A 25-year-old woman saw limited improvement in brain fog and headaches after a 10-day course, with symptoms returning to baseline post-treatment.
-
Case #4: A 51-year-old man experienced symptom reduction for four weeks after a 15-day course, with improvements in PEM, paresthesia, and tinnitus.
-
Case #5: An adult woman reported the disappearance of severe brain fog and improvement in respiratory sensitivity after a 10-day course.
-
Case #6: A 40-year-old man had near-complete remission of symptoms by day 3 of a 5-day course, with symptoms slowly returning post-treatment.
-
Case #7: A 29-year-old man noticed slight improvement in fatigue and brain fog during a 15-day course, but returned to baseline after treatment.
-
Case #8: A 35-year-old woman experienced no change in Long COVID symptoms after an extended course.
-
Case #9: A 34-year-old woman saw no change in symptoms after a 15-day course.
-
Case #10: A 45-year-old woman experienced temporary improvement during a 5-day course but returned to baseline post-treatment.
-
Case #11: A 33-year-old woman improved overall functioning after a 5-day course, with symptoms persisting but less severe.
-
Case #12: A 41-year-old woman returned to her pre-reinfection baseline after a 10-day course during acute infection.
-
Case #13: A 55-year-old transgender person experienced several days without fatigue or significant pain after a 7.5-day course during acute infection, with symptoms returning to baseline within 2-3 weeks.
Discussion
This case series suggests that extended courses of nirmatrelvir/ritonavir may benefit some individuals with Long COVID, though outcomes vary. The treatment was generally well-tolerated, with some patients experiencing significant improvements in symptoms. These findings support the need for further research, including randomized clinical trials, to explore the efficacy and safety of extended antiviral therapy for Long COVID. The heterogeneity of Long COVID symptoms and responses to treatment underscores the importance of personalized approaches in future studies.
